Allergan and ExonHit Therapeutics Designate Target for High Throughput Screening; ExonHit Therapeutics Identifies Novel Target.Business Editors/Health/Medical Writers BIOWIRE2K PARIS--(BUSINESS WIRE)--Nov. 19, 2003 ExonHit Therapeutics announced that Allergan, Inc. (AGN AGN Again (Amateur Radio) AGN Active Galactic Nucleus AGN Acute Glomerulonephritis AGN Accountants Global Network AGN Air Gabon (ICAO code) ), a global specialty pharmaceutical company, has initiated high throughput screening on a target generated pursuant to a 10 month old strategic alliance between the companies. ExonHit is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. that discovers neurodegenerative and cancer therapeutics and diagnostics based on alternative RNA splicing RNA splicing n. See splicing. RNA splicing, n the process by which base pairs that interrupt the continuity of genetic information in deoxyribonucleic acid are removed from the precursors of messenger . ExonHit has delivered to Allergan a small molecule target that shows efficacy in a previously unrecognized pathway identified utilizing DATAS(TM), ExonHit's proprietary gene profiling technology. This target will begin high throughput screening. The strategic alliance was formed in December 2002 with the purpose of developing new drugs in the field of neurodegenerative diseases neurodegenerative diseases diseases characterized by neurodegeneration. Lesions are microscopic only but in chronic disease with massive involvement there may be grossly visible atrophy of affected nervous tissue. , pain and ophthalmology. The dual goals of the agreement are to identify new molecular targets based on ExonHit Therapeutics' gene profiling DATAS(TM) technology and to work collaboratively toward developing and commercializing unique compounds and commercial products based on these targets. Les Kaplan Executive Vice President and President of R&D at Allergan stated, "I am pleased both with the productive working relationship and with the progress made to date". "Rapidly delivering a designated target and expecting to deliver one or two more within the next five months exemplifies the power of DATAS(TM) and of our ability to analyze the role of alternative RNA splicing events in disease," commented Fabien Schweighoffer, Executive VP, Research, ExonHit Therapeutics, "I view the ExonHit approach as an engine for drug discovery and I'm pleased this approach is moving the alliance with Allergan in a promising direction and with impressive speed-- it's a process that has worked well for our diagnostic collaborations and internal therapeutic programs." ExonHit's therapeutic pipeline includes a compound for Amyotrophic Lateral Sclerosis amyotrophic lateral sclerosis (ALS) (ā'mīətrōf`ik, sklĭrō`sĭs) or motor neuron disease, (commonly known as Charcot or Lou Gehrig's disease Lou Geh·rig's disease n. See amyotrophic lateral sclerosis. ) which is currently in a large Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II (400 patients) for evaluation of its safety and its efficacy on survival. This study is expected to be completed in the Fall 2004. A Phase I trial is planned for a small molecule therapeutic with indications in several neurodegenerative diseases and retinitis pigmentosa Retinitis Pigmentosa Definition Retinitis pigmentosa (RP) refers to a group of inherited disorders that slowly lead to blindness due to abnormalities of the photoreceptors (primarily the rods) in the retina. . Furthermore, two new chemical entities with anti-angiogenesis properties are in pre-clinical stages for the treatment of cancer and ocular revascularization disorders (the leading cause of blindness). In addition to its therapeutic programs, ExonHit has ongoing diagnostic collaborations with Roche Applied Sciences and bioMerieux. Internal diagnostic projects include a prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. diagnostic test, based on alternatively spliced isoforms of PSA (Professional Services Automation) An information system designed to organize, track and manage all opportunities, work, resources, costs, revenues and invoices to improve the productivity and efficiency of the workforce. and KLK KLK Kallikrein KLK Ke Lo Ke (que lo qué) KLK Kommando Luftbeweglicke Kräfte (Air Mobile Force Command, FRG) KLK Key Loss Key 2, and a blood-based diagnostic test for colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. . ExonHit intends to out-license both tests in the near future. Forward-Looking Statements This press release contains "forward-looking statements", such as the statements of Dr. Kaplan and Dr. Schweighoffer, and the parties' goals of developing drug compounds and commercial products. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the parties' expectations and projections. Risks and uncertainties include general industry and pharmaceutical market conditions; general domestic and international economic conditions; technological advances and patents attained by competitors; challenges inherent in new product marketing such as the unpredictability of market acceptance for a new pharmaceutical product or approved indication approved indication, n 1. reliable signs that a certain remedy should be used. Not synonymous with “authorized.” 2. FDA-approved condition for a drug or other treatment that allows labeling. ; potential difficulties in manufacturing a new product formulation; domestic and foreign health care reforms; and trends toward managed care and health care cost containment; and governmental laws and regulations affecting domestic and foreign operations. About ExonHit Therapeutics www.exonhit.com ExonHit Therapeutics is a privately-held company whose mission is to develop novel therapeutics and diagnostics for neurodegenerative diseases and cancer. The company is a leader in alternative RNA splicing holding a premier scientific and intellectual property position in the field. Utilizing DATAS(TM), the company's proprietary gene profiling technology, allows the detection of disease-relevant changes in mRNA populations resulting from alternative RNA splicing events, providing key insight into biological causes of pathology. DATAS(TM) stands for: Differential Analysis of Transcripts with Alternative Splicing. DATAS(TM) is central to internal drug discovery programs but the profiling technology also has broad applications. ExonHit has several external therapeutic and diagnostic collaborators, and has used the technology to capitalize on the growing needs for pharmacogenomic tools, and toxicity prediction assays. ExonHit Therapeutics, founded in 1997, is headquartered in Paris, France and has a US facility in Gaithersburg, Maryland. The company has 70 employees worldwide and has raised a total of EUR EUR In currencies, this is the abbreviation for the Euro. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 47 million. About Allergan, Inc. Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion